What changed: Astrocytoma, IDH-mutant (grades 2 to 4)

When this page itself was last checked or edited.

Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12 (INDIGO): first targeted therapy for low-grade glioma

Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12

A milestone in how this cancer is treated.

PFS 27.

Mellinghoff and colleagues (NEJM): median progression-free survival 27.7 versus 11.1 months.

A milestone in how this cancer is treated.

Adjuvant temozolomide: overall survival hazard ratio 0.

A milestone in how this cancer is treated.

Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.

Buckner and colleagues (NEJM) report median overall survival of 13.3 years against 7.8 years with radiotherapy alone.

A milestone in how this cancer is treated.

Yan and colleagues (NEJM) show IDH mutations in most grade 2 and 3 gliomas and their better prognosis.

Parsons and colleagues sequence glioblastoma exomes (Science) and find IDH1 mutations concentrated in younger patients and secondary tumours.

OS 14.